Brief Title
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
Official Title
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks
Brief Summary
SHARE: Simple HAART with Abacavir, Reyataz, and Epivir
Detailed Description
Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA <50 copies/mL at entry
Study Phase
Phase 4
Study Type
Interventional
Condition
HIV Infections
Intervention
atazanavir (Reyataz)
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Start Date
August 2006
Eligibility Criteria
Inclusion Criteria: - Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen - Viral load <50 copies/ml Exclusion Criteria: - Viral load >50 copies/ml - Having taken more than one antiretroviral regimen
Gender
All
Ages
18 Years - N/A
Contacts
Richard A Elion, MD, , [email protected]
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT00426296
Organization ID
COL102060
Study Sponsor
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Collaborators
GlaxoSmithKline
Study Sponsor
Richard A Elion, MD, Principal Investigator, Whitman-Walker Clinic
Verification Date
October 2007